title: Association study of NRXN3 polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population.
abstract: Recent researches have implicated that mutations in the neurexin-3 (NRXN3) gene on chromosome 14q24.3-q31.1 might play a role in addiction, autism, and obesity. In order to explore the association of NRXN3 polymorphisms with schizophrenia, we examined seven single nucleotide polymorphisms (SNPs) in NRXN3 spanning 1.33 Mb of this gene, in a Chinese Han sample of 1214 schizophrenic patients and 1517 healthy control subjects. Our results showed that three SNPs were associated with schizophrenia (rs7157669: A>C, p=0.006; rs724373: C>T, p=0.014; rs7154021: C>T, p=0.018). After being corrected for multiple tests, the association of rs7157669 remained significant but those for two others were modest. According to the linkage disequilibrium pattern, the 7 SNPs may construct 3 haplotype blocks. Several haplotypes were significantly associated with schizophrenia, constructed by rs11624704-rs7157669-rs724373 (AAC, p=0.003; ACT, p=0.007, both remained significant after permutation tests), rs7154021-rs7142344 (TT, p=0.024; CT, p=0.012), respectively. Among the patients, 326 ones at first onset have received 6-week monotherapy of risperidone. Further analyses showed that two SNPs were associated with percentage of bodyweight gain following a 6-week therapy of risperidone (rs11624704: p=0.03; rs7154021: p=0.008) and rs7154021 remained significant after permutation test. Our findings suggested that NRXN3 might represent a major susceptibility gene for schizophrenia and have a role in bodyweight gain related to therapy of risperidone in Chinese Han population.
authors.affiliation: Institute of Mental Health, Peking University, Beijing 100191, China.
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Hu
authors.forename: Jishui
authors.initials: J
authors.lastname: Zhang
authors.forename: Chao
authors.initials: C
authors.lastname: Jin
authors.forename: Weifeng
authors.initials: W
authors.lastname: Mi
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.forename: Wenbin
authors.initials: W
authors.lastname: Ma
authors.forename: Cuicui
authors.initials: C
authors.lastname: Ma
authors.forename: Yongfeng
authors.initials: Y
authors.lastname: Yang
authors.forename: Wenqiang
authors.initials: W
authors.lastname: Li
authors.forename: Hongxing
authors.initials: H
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Du
authors.forename: Keqing
authors.initials: K
authors.lastname: Li
authors.forename: Chenxing
authors.initials: C
authors.lastname: Liu
authors.forename: Lifang
authors.initials: L
authors.lastname: Wang
authors.forename: Tianlan
authors.initials: T
authors.lastname: Lu
authors.forename: Hongyan
authors.initials: H
authors.lastname: Zhang
authors.forename: Luxian
authors.initials: L
authors.lastname: Lv
authors.forename: Dai
authors.initials: D
authors.lastname: Zhang
authors.forename: Weihua
authors.initials: W
authors.lastname: Yue
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D044466:Asian People; D004247:DNA / Q000235:genetics; D005260:Female; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D015810:Linkage Disequilibrium; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D009419:Nerve Tissue Proteins; C082354:neurexin IIIalpha; D004247:DNA; D018967:Risperidone